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Background: Cytokines may be elevated in tumor and normal tissues following irradiation. Cytokine expression in
these tissues may predict for toxicity or tumor control. The purpose of this pilot study was to determine the
feasibility of measuring local salivary cytokine levels using buccal sponges in patients receiving chemo-radiation for
head and neck malignancies.
Patients and methods: 11 patients with epithelial malignancies of the head and neck were recruiting to this study.
All patients received radiotherapy to the head and neck region with doses ranging between 60 – 67.5 Gy.
Chemotherapy was delivered concurrently with radiation in all patients. Salivary samples were obtained from high
dose and low dose regions prior to treatment and at three intervals during treatment for assessment of cytokine
levels (IL-4, IL-6, IL-8, IL-10, EGF, MCP-1, TNF-α, and VEGF).
Results: Cytokine levels were detectable in the salivary samples. Salivary cytokine levels of IL-4, IL-6, IL-8, EGF, MCP-1,
TNF- α , and VEGF were higher in the high dose region compared to the low dose region at all time points (p< 0.05).
A trend toward an increase in cytokine levels as radiation dose increased was observed for IL-6, IL-8, MCP-1, and TNF-α.
Conclusion: Assessment of salivary cytokine levels may provide a novel method to follow local cytokine levels during
radiotherapy and may provide a mechanism to study cytokine levels in a regional manner.
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Ionizing radiation is known to increase the expression of a
number of cytokines which are involved in inflammation
and wound healing. These cytokines may be important in
recruitment of inflammatory cells, initiation of wound re-
pair, and development of toxicity. Cytokine levels detected
in the plasma have been correlated to toxicity, such as
pneumonitis [1-3]. Cytokine concentrations in tumor and
circulating cytokines have also been correlated to
prognosis.
Measurement of cytokines in the clinical setting typ-
ically requires plasma sampling. Plasma sampling
requires consistent and rapid collection, processing,* Correspondence: citrind@mail.nih.gov
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reproduction in any medium, provided the orand storage techniques to minimize the risk of platelet
deregulation which may falsely elevate the levels of a
variety of cytokines [4-7]. Plasma levels of cytokines can
also be impacted by a variety of inflammatory condi-
tions, complicating correlations to radiotherapy in
patients with inflammatory comorbidities. For these rea-
sons, sampling plasma for research purposes can be dif-
ficult to perform and interpret in multi-institutional
trials or in the community setting. A simple, non-inva-
sive method for detecting local expression of cytokines
may avoid many of these logistical and technical chal-
lenges of plasma sampling. In addition, assessment of
local cytokine levels via longitudinal sampling in
patients undergoing therapy may allow for an under-
standing of the temporal nature of cytokine elevation
during radiation and correlation with tumor response
and toxicity.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Citrin et al. Radiation Oncology 2012, 7:64 Page 2 of 6
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using an ophthalmic sponge (Merocel) to sample saliva
and to detect cytokines in head and neck cancer patients
undergoing a course of chemoradiotherapy. Ophthalmolo-
gic sponges have been used to collect secretions from
human subjects for cytokine evaluation and viral recovery
in prior studies [8-11]. We evaluated the ability to detect
differences in cytokine concentrations in proximity to
tumor (high dose region) compared to areas in the mouth
planned to receive lower doses of irradiation distant to
the tumor site (low dose region). Finally, we determined




All patients were enrolled on an IRB approved protocol at
the University of Utah. Patients were eligible for this study
if they were at least 18 years of age, had a Karnofsky per-
formance score >50, were scheduled to receive fractio-
nated radiotherapy for a pathologically documented head
and neck malignancy, and provided informed consent.
Patients treated with intensity modulated radiotherapy
and concurrent chemotherapy were eligible. Patients in
whom the target region was inaccessible to radiation were
excluded. For example, pateints with hypopharyngeal
tumors were enrolled only if a nodal target volume was in
proximity to an anticipated sampling site.
Simulation, planning, and treatment
All patients were simulated supine with an aquaplast
mask. Spiral CT was performed at 2.5 mm slice thickness,
and treatment planning was performed using Eclipse (Var-
ian Medical Systems, Palo Alto, CA). All patients
received definitive chemoradiotherapy. Treatment plans
were generated with intensity modulated radiation ther-
apy or conformal radiotherapy per standard of care de-
pending on tumor location and characteristics. Patients
were evaluated weekly during the six-week course of
treatment to evaluate acute radiation toxicity and tumor
response. Following therapy, patients were followed
with serial clinical examinations and imaging studies to
evaluate for evidence of tumor recurrence and toxicity
recovery.
Specimen collection
Specimens were obtained pretreatment and after delivery
of 10, 20, and 30 Gy of radiation. All specimens were col-
lected within 30 minutes following radiation treatment. A
sterile Merocel sponge (Medtronic, Jacksonville, FL) was
pre-wet with 100 uL of sterile saline before use. The high
dose region for sampling was selected to be in proximity to
tumor, if possible, and so that it was in a region encom-
passed by the 90% or higher isodose line. The site forsampling for the low dose specimen was chosen so that the
dose received to the area was less than 15% of the prescrip-
tion dose. The anatomic location of the site of sampling for
each patient was recorded in their chart. The sponge was
placed in the location of sampling without rubbing or
movement for 60 seconds and immediately placed in a
50 mL conical vial. In each patient, samples were obtained
inside the high dose region and at a site distant to the
tumor in a low dose region, typically the buccal mucosa.
Samples were obtained pretreatment and after a minimum
of 10 Gy (second week), 20 Gy (third week), and 30 Gy
(fourth week) of treatment. Samples were immediately fro-
zen and stored at −80°C until shipment on dry ice. Shipped
specimens were stored at −80°C until use.Recovery of cytokines from Merocel sponges
Sponges were thawed on ice and weighed prior to recov-
ery. Sponge tips were separated from the handle with
sterile technique and were incubated with 300 uL of ice
cold extraction buffer containing 10% fetal calf serum in
0.25 M NaCl. Sponges were soaked on ice in extraction
buffer for 30 minutes. Sponges and liquid were trans-
ferred to co-stat Spin-x centrifuge tubes and centrifuged
at 16,000 x g for 20 minutes at 4°C. The sponge was dis-
carded and the supernatant was utilized for further
analysis.Evaluation of cytokine levels
Concentrations of IL-4, IL-6, IL-8, IL-10, MCP-1, TNF-α,
VEGF, and EGF in saliva were analyzed with the Luminex
fluorescent technique, utilizing Milliplex Magentic Beads
(Millipore, Billerica, MA) according to the manufacturers’
instruction. Briefly, 25 uL of assay buffer, 25 uL of sample
or standard, 25 uL of matrix solution, and 25 uL of mixed
bead were added to each well of a 96 well plate and incu-
bated overnight on an orbital shaker at 4°C. Samples and
standards were plated in triplicate. After washing, 25 uL
of detection antibody was added to each well and incu-
bated for one hour at room temperature. Following incu-
bation, 25 uL of streptavidin-phycoerythrin was added to
each well and incubated on an orbital shaker for 30 min-
utes at room temperature. The plate was washed and 150
uL of sheath fluid was added to each well. The levels of
fluorescence in each standard, quality control, and sample
were detected with the LuminexW 200™ (Luminex Corpor-
ation, Austin, TX). Data was subsequently analyzed using
the Bio-plex manager software (Bio-Rad Laboratories, Inc.
Hercules, CA). Cytokine concentrations were obtained by
interpolation of the standard curve using stepwise five-
fold dilution of protein standards. Standard curves were
generated for each analyte with the Bio-plex manager soft-
ware and sample concentrations were calculated from the
standard curve.
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15 pg/ml for the cytokines studied. The intra-assay preci-
sion measured as the coefficient of variation for the studied
cytokines ranged from 3.2 to 11.2% The interassay preci-
sion measured as the coefficient of variation for the studied
cytokines ranged from 6.4 to 15% All samples were
batched by patient and a total of two plates were required
to assay all samples in duplicate.
Because the volume of sample cannot be standardized
with the sponge technique, concentrations of cytokines
were normalized with a previously reported dilution fac-
tor used for sponge based collection methods [9,11] with
the formula dilution factor = [(x - 0.064 gm) + 0.32 gm]/
(x – 0.064 gm) where x is the weight of the sponge with
sample, 0.064 is the average weight of 10 dry sponges,
and 0.32 gm is the weight of the 300 uL of extraction
buffer added for elution. The levels of each cytokine
were evaluated between local and distant sampling as
well as over the course of treatment at each location.
Results
Patient, tumor, and treatment characteristics
Eleven patients were included in this pilot study. Tumor
locations of the primary tumor in these patients were
oral cavity (n = 2), oropharynx (n = 5), larynx (n = 2), and
hypopharynx (n = 2). Tumor characteristics are described
in detail in Table 1. The mean total dose delivered was
66.68 Gy (range: 60–67.5 Gy), and the mean dose per
fraction was 2.2 Gy (Range: 2.0-2.25 Gy). The mean
number of days on treatment was 44 (Range: 41–47). A
seven-field technique using 6-MV photon beams was
used for nine of eleven patients. Opposed lateral fields
with 6-MV photon beams were used for the remaining















N3 1Salivary cytokine levels
Salivary cytokine levels were uniformly elevated in the
high dose region compared to the low dose region at
baseline. Specifically, for EGF, IL-4, IL-10, MCP-1, TNF-α,
and VEGF the mean baseline local levels were significantly
elevated compared to baseline distant levels (p< 0.05,
Table 2). Additionally, with the exception of IL-6, levels of
these cytokines at the high dose region remained signifi-
cantly higher than levels in the low dose region at all or
most doses of radiation, suggesting that regional levels of
cytokines may be detectable in saliva and may correlate
to the proximity to tumor. The trends are represented
graphically in Figures 1 and 2.
Changes in salivary cytokine levels over time
As radiation dose increased, there was a trend towards
increased IL-6, IL-8, MCP-1 and TNF-α levels within a
sampling site (high dose region or low dose region), but
this did not reach the predetermined level of significance
for any analyte. In this small sample, there were no signifi-
cant correlations between cytokine levels at baseline or
changes in cytokine levels over time and tumor grade,
tumor stage, nodal stage, local recurrence, or toxicity.
However, a number of interesting non-significant trends
were observed, For example, levels of IL-10, an anti-inflam-
matory cytokine, in saliva at each dose level compared to
baseline were higher in patients with high grade mucositis
compared to those with low grade mucositis (Figure 3).
Discussion
Radiation, delivered alone or with chemotherapy, is fre-
quently used in the definitive management of a range of
malignancies, and is the primary treatment for advanced
Head and Neck cancers. Due to concerns for healing dur-
ing and after the delivery of radiation, assessment of
tumor and normal tissue in the radiated field through bi-
opsies or invasive techniques for correlative assays may be
limited. Sampling of blood to assess changes in markers of
tumor response or normal tissue toxicity may be compli-
cated by dilution in the systemic circulation and back-
ground alterations due to other illnesses or injury. A
minimally invasive technique for sampling local effects of
radiation on tumor and normal tissue may provide a
method to predict which patients will develop severe tox-
icity or allow prognostication earlier in the treatment
course. Furthermore, a relatively simple, minimally inva-
sive method for sampling could be incorporated into
multi-institutional trials and simplify collection of high-
quality specimens.
We have evaluated the feasibility of the collection of
saliva during a course of irradiation in a pilot experi-
ment. We were able to collect salivary samples from
patients serially during the course of irradiation. These
samples were not processed prior to storage and
Table 2 Basal cytokine levels









EGF 198.6-1037.56 346.27 40.53-508.61 86.40 p = 0.0001
IL-4 10.64-160.10 56.45 3.04-32.69 10.42 p = 0.006
IL-6 4.1-293.07 36.46 1.88-143.66 7.44 p = 0.015
IL-8 59.29-7600.26 562.36 12.1-3725.62 174.12 p = 0.032
IL-10 5.47-49.59 21.30 2.5-24.31 3.69 p = 0.0003
MCP-1 81.05-620.61 194.17 9.32-173.55 60.24 p = 0.0004
TNF-α 1.81-22.32 8.54 0.9-10.94 1.73 p = 0.0003
VEGF 89.67-881.10 278.63 34.36-431.91 51.07 p = 0.0003
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method of sampling for multi-institutional trials in
which significant processing requirements can poten-
tially negatively impact adherence to sample collection
schedules and the uniformity of sample quality. Despite
the lack of additional processing at the time of sampling,
we were able to successfully recover all of our target
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Figure 1 IL-8, MCP-1, IL-10, and VEGF levels in saliva before and after
concentrations corrected for wet weight of the collecting sponge. Each po
radiation dose region, LD region: outside of the high dose region, bar: medBuccal cell samples have been evaluated as a correlate
of mucositis after radiation in a prior study [12], but this
feasibility study did not evaluate a broad range of cyto-
kines and evaluated RNA levels from buccal mucosa in-
stead of levels of cytokines in saliva as in our study.
Assessment of the protein levels in saliva is feasible in
our study and changes based on location of sampling
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irradiation. Salivary cytokine levels were assessed with Milliplex with
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Figure 2 IL-4, EGF, TNF-alpha, and IL-6 levels in saliva before and after irradiation. Salivary cytokine levels were assessed with Milliplex with
concentrations corrected for wet weight of the collecting sponge. Each point represents a single patient sample. HD region: within the high
radiation dose region, LD region: outside of the high dose region, bar: median.
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increasing levels with increasing dose delivered was


























Figure 3 Correlation between IL-10 levels in saliva and
mucositis. IL-10 levels were assessed with Milliplex with
concentrations corrected for wet weight of the collecting sponge.
IL-10 levels at 10 Gy and 30 Gy were normalized to baseline for all
patients. Patients with Grade 2 or higher mucositis had a higher
relative IL-10 concentration compared to those with Grade 0 or 1
mucositis. G: grade, bars: mean, error bars: SD.provide more impressive differences in cytokine levels in
saliva compared to baseline measurements. This would
likely be related to more tissue changes such as inflamma-
tion and desquamation due to higher doses of radiation.
We were specifically interested in early changes, and conse-
quently focused on the first half of definitive chemoradia-
tion. Future studies will assess if greater differences can be
observed at higher doses compared to baseline and if these
differences correlate with tumor or normal tissue out-
comes. One important question that will need to be
answered in future studies is whether dose to salivary
glands on the side of sampling correlates to changes in sal-
ivary cytokine levels. It is conceivable that the salivary gland
itself may alter salivary cytokine levels to a measurable
degree.
The pattern of change in traditional pro-inflammatory
cytokines we evaluated may provide evidence of acute in-
flammation during a course of radiotherapy. For example,
MCP-1 and IL-8 levels progressively increased during the
course of radiation, while other cytokines, such as IL-4
and EGF were elevated in closer proximity to tumor with
no trend for an increase in concentration during the
course of radiation. Both MCP-1 and IL-8 result in inflam-
matory cell recruitment and may reflect local inflamma-
tion. A number of other possible analytes exist which
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to acute inflammation and mucosal toxicity.
These findings raise the possibility that a technique
such as salivary sampling at baseline may provide infor-
mation that could be prognostic or predictive of re-
sponse to therapy. Amelioration of cytokine levels in the
future may be able to reduce adverse effects of radiation
such as fibrosis or osteoradonecrosis. Again, additional
studies in larger numbers of patients will be needed to
address these questions.
Conclusions
Sampling of salivary cytokine levels in patients undergo-
ing radiotherapy for head and neck malignancies is feas-
ible and may provide a non-invasive biomarker of the
local effects of irradiation on tumor and normal tissue.
Additional studies will be needed to clarify the potential
applications and limitations of this technique.
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